Cargando…
Integrative bioinformatics analysis and experimental validation of key biomarkers for risk stratification in primary biliary cholangitis
BACKGROUND: Primary biliary cholangitis (PBC) is an autoimmune liver disease, whose etiology is yet to be fully elucidated. Currently, ursodeoxycholic acid (UDCA) is the only first-line drug. However, 40% of PBC patients respond poorly to it and carry a potential risk of disease progression. So, in...
Autores principales: | Tian, Siyuan, Hu, Yinan, Zhang, Miao, Wang, Kemei, Guo, Guanya, Li, Bo, Shang, Yulong, Han, Ying |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10544390/ https://www.ncbi.nlm.nih.gov/pubmed/37784152 http://dx.doi.org/10.1186/s13075-023-03163-y |
Ejemplares similares
-
Immunoglobulin M: A Neglected Serum Biomarker in Treatment‐Naive Primary Biliary Cholangitis With Normal Alkaline Phosphatase
por: Ding, Dawei, et al.
Publicado: (2022) -
Efficacy and safety of fenofibrate add-on therapy in patients with primary biliary cholangitis refractory to ursodeoxycholic acid: A retrospective study and updated meta-analysis
por: Guoyun, Xuan, et al.
Publicado: (2022) -
Identification of AKR1B10 as a key gene in primary biliary cholangitis by integrated bioinformatics analysis and experimental validation
por: Wang, Huiwen, et al.
Publicado: (2023) -
Risk Stratification in Primary Biliary Cholangitis
por: Martini, Francesco, et al.
Publicado: (2023) -
Symptoms Burden and Health-related Quality of Life in Chinese Patients with Primary Biliary Cholangitis
por: Liu, Yansheng, et al.
Publicado: (2021)